InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,431.60
(
-0.04%
)
US TECH 100
19,168.00
(
0.52%
)
Dow Jones
38,589.16
(
-0.15%
)
Brent Oil
82.28
(
0.00%
)
Bitcoin
66,218.59
(
0.32%
)
Post# of 252190
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: genisi post# 142805

Thursday, 05/31/2012 1:37:33 PM

Thursday, May 31, 2012 1:37:33 PM

Post# of 252190
I found the data from phase II of the two BRAF inhibitors and with the caveat of comparing results from different trials, they seem to be in the same ballpark.

BRIM2 phase II data for Zelboraf (vemurafenib)

http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84075

BRF113710 phase II study of dabrafenib (GSK2118436)

http://www.gsk-clinicalstudyregister.com/result_comp_list.jsp?phase=Phase+2&studyType=All&population=All&marketing=All&compound=dabrafenib
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up